ERBB2 and cancer: An increasing number of studies have highlighted that key cancer-associated neoantigens and spliceosomal proteins are frequently altered in cancer, leading to pathogenesis and/or treatment resistance (57), such as in the HER2 and BRCA1 isoforms (58, 59).